Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov
Condition: Breast Cancer
Study Type: Non-Interventional
Study Start Date: 01/23/2019
Study Completion Date: 12/2027
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.